Market Overview

This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says


Eli Lilly and Co (NYSE: LLY) will release key data Thursday on its prospective autoimmune drug baricitinib that an analyst said will become a market leader with 2023 sales of $2.5 billion.

Credit Suisse's Vamil Divan boosted his price target on Lilly about 4 percent Monday to $75.

Divan also said AbbVie Inc. (NYSE: ABBV) will post interim data on filgotinib autoimmune treatment in July or August

Divan said filgotinib might hit 2023 sales of $2.2 billion, and raised his AbbVie target more than 4 percent to $72.

The market for drugs aimed at autoimmune disease will grow by a third in 10 years and get roiled by a raft of new products, according to Divan.

The group of diseases includes rheumatoid arthritis, multiple sclerosis and a host of other maladies caused by disorders related to the immune system.

Orally dosed drugs will have the biggest impact on the autommune market, Divan said.

Growth in the market will initially get fueled by current drugs classed as biologic response modifiers and then expand further with new entries in the group made more attractive by new, oral dosing options.

Divan raised his target on Johnson & Johnson (NYSE: JNJ) about 1 percent to $109, saying its pipeline assets guselkumab and sirukumab will help fend off increasing competition for its established products.

Merck & Co., Inc. (NYSE: MRK) looks like an unequivocal looser in the emerging market for autoimmune drugs, and Divan shaved his target on the company by 1.6 percent to $61.

Latest Ratings for LLY

Dec 2019MaintainsBuy
Dec 2019MaintainsOverweight
Dec 2019UpgradesEqual-WeightOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Credit Suisse Vamil DivanAnalyst Color Health Care Price Target FDA Analyst Ratings General


Related Articles (JNJ + ABBV)

View Comments and Join the Discussion!

Latest Ratings

RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at